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Results: Since today 20 pts have been enrolled. Median age was 59 
yrs (44-74). 17 males and 3 females. PS1 65% and PS 2 30%. All but 
two had ED. Median number of metastatic sites was 2 (1-5), including 
2 pts with brain metastasis. Median number of cycles was 8 (1-12). A 
total of 133 cycles were administered. Considering all cycles, WHO 
grade 3 and 4 toxicity was as follows: neutropenia 3%, with no febrile 
neutropenia, thrombocytopenia 1%, anemia 3%. There was not grade 
3-4 non-hematological toxicity. In an ITT analysis overall response rate 
was 60% (12/20) including 20% (4/20) complete responses. At time of 
this analysis 55% of pts were dead and Kaplan Meyer actuarial suvival 
was 47,1 weeks (95% CI: 27-67). The 1 year suvival rate was 39 %.
Conclusions: Biweekly Cb plus G is a feasible and active regimen as 
ﬁrst line chemotherapy for pts with metastatic SCLC. Median suvival 
time seems to be in the range of other regimens commonly used. Our 
results show this schedule convenient for pts in a palliative outpatient 
setting.
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Background: The intravenous (IV) method of cytotoxic chemotherapy 
administration imposes not only a time burden on patients and facili-
ties, but also has cost implications for payers. This study aims to assess 
the costs associated with the IV administration of chemotherapies 
for patients with all forms of lung cancer and for a subset of patients 
with small cell lung cancer (SCLC) in a large employer-payer claims 
database.
Methods: Using medical claims data from 5.5 million beneﬁciaries 
between 01/01/1998 and 01/31/2006, we identiﬁed 8,605 patients with 
lung cancer (ICD-9 codes 162.3-162.9, 176.4, or 197.0) receiving IV 
chemotherapies. We then identiﬁed a subset of 1,087 patients likely to 
have SCLC by selecting those receiving chemotherapy regimens princi-
pally used to treat SCLC (cisplatin/etoposide, cisplatin/irinotecan, car-
boplatin/etoposide, or topotecan) and excluding patients receiving PET 
scan imaging procedures associated with non-small cell lung cancer 
(NSCLC). Average total costs per day of IV chemotherapy administra-
tion (including drug, administration costs, etc.) were computed for 
all patients and for the SCLC subset based on the actual amount paid. 
Costs were also computed separately for: IV chemotherapy drugs, IV 
chemotherapy administration procedures, and other visit-related drugs 
and services (e.g., IV administration of other drugs to treat side effects 
of chemotherapies, evaluation and management, and laboratory tests). 
Results: Average total cost per day of IV chemotherapy administra-
tion for patients with all forms of lung cancer was $1,112, with $652 
(58.6%) attributable to IV chemotherapy drugs, $85 (7.7%) to IV 
chemotherapy administration procedures, and $375 (33.7%) to other 
visit-related drugs and services. Among patients with SCLC, average 
total daily cost was $841, with $451 (53.6%) attributable to IV chemo-
therapy drugs, $88 (10.5%) to IV chemotherapy administration, and 
$302 (35.9%) to other visit-related drugs and services. 
Conclusions: IV chemotherapy administration procedures and other 
visit-related drugs and services accounted for 41.4% and 46.4% of total 
costs in patients with all forms of lung cancer and those with SCLC, 
respectively. The increased availability and use of oral chemotherapy 
drugs in lung cancer should not only enhance patient convenience, but 
also provide savings to payers as costs associated with IV administra-
tion, and potentially other visit-related drugs and services, may be 
avoided.
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Background: SCLC is a highly symptomatic disease with poor 
survival in previously treated patients. To evaluate the role of chemo-
therapy, a multicenter trial randomized 141 previously treated patients 
to receive either OT + BSC or BSC only. This trial evaluated survival, 
response and symptoms. Median survivals were 25.9 weeks on OT 
+ BSC vs 13.9 weeks on BSC (p = 0.01) (O’Brien et al JCO 2006). 
“Disease control” (partial response [PR] + stable disease [SD]) was 
achieved by 51% of patients receiving OT + BSC; no patient on BSC 
was reported to have a major response, although response was not an 
endpoint for this group. In that symptomatic beneﬁt is a major goal 
beyond survival improvement in this difﬁcult setting, we undertook this 
analysis to determine if there is an additional value to major response 
versus stable disease in patients receiving OT chemotherapy.
Methods: The patient reported outcome instrument used in this trial 
was the PSALC (a measure of patient self-reported lung symptoms). 
Association between baseline PSALC total scores and ECOG perfor-
mance status (PS) was tested using a contrasted group analysis. We 
used the investigators evaluation of response (PR or SD) in the 71 pa-
tients on the OT arm and analyzed these groups by the patients’ PSALC 
total scores.
Results: Patients with a lower functional status based on ECOG PS 
at baseline reported more severe symptoms (higher PSALC score): 
mean PSALC score=12.31, 16.37, 17.58 for ECOG score=0, 1, 2, 
respectively, p=0.0002. Mean changes in PSALC score from baseline 
demonstrated an association between tumor response and symptom 
control (p=0.0016). For patients with PR (N=5), mean baseline PSALC 
was 15.07, while mean on-treatment PSALC was 12.64, representing a 
change from baseline of -2.43 and a 16.12% improvement in symp-
toms. In contrast, for patients with SD (N=31) there was no appreciable 
change in PSALC between baseline and on-treatment (mean PSALC 
was 15.33 and 15.35, respectively with change from baseline of 0.01). 
Conclusions: Patients who achieved a major response on OT treat-
ment reported signiﬁcantly better symptom relief than those whose best 
response was SD. In that the decision to treat in the second-line setting 
can be a difﬁcult one, these results indicate added symptomatic beneﬁt 
for patients able to achieve major response, which only occurs with 
treatment.
